Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Murray

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Trials|January 8, 2020
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trialFiona Gaughran, Dominic Stringer, Michael Berk, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Schizophrenia Bulletin Open|September 27, 2021
Development and Validation of a Nonremission Risk Prediction Model in First-Episode Psychosis: An Analysis of 2 Longitudinal StudiesSamuel P Leighton, Rajeev Krishnadas, Rachel Upthegrove, et al.
Psychological Medicine|February 5, 2025
Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factorsLaura Ferraro, Marta Di Forti, Daniele La Barbera, et al.
Human Molecular Genetics|January 15, 2010
A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophreniaAndrés Ingason, Ina Giegling, Sven Cichon, et al.
Molecular Psychiatry|August 29, 2023
Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analysesNerisa Banaj, Daniela Vecchio, Fabrizio Piras, et al.
Human Molecular Genetics|October 24, 2008
Disruption of the neurexin 1 gene is associated with schizophreniaDan Rujescu, Andres Ingason, Sven Cichon, et al.
Molecular Psychiatry|October 15, 2024
Methylomic signature of current cannabis use in two first-episode psychosis cohortsEmma L Dempster, Chloe C Y Wong, Joe Burrage, et al.
Psychological Medicine|October 17, 2019
An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortiumTing Yat Wong, Joaquim Radua, Edith Pomarol-Clotet, et al.
Nature|August 1, 2008
Large recurrent microdeletions associated with schizophreniaHreinn Stefansson, Dan Rujescu, Sven Cichon, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Trials|January 8, 2020
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trialFiona Gaughran, Dominic Stringer, Michael Berk, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Schizophrenia Bulletin Open|September 27, 2021
Development and Validation of a Nonremission Risk Prediction Model in First-Episode Psychosis: An Analysis of 2 Longitudinal StudiesSamuel P Leighton, Rajeev Krishnadas, Rachel Upthegrove, et al.
Psychological Medicine|February 5, 2025
Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factorsLaura Ferraro, Marta Di Forti, Daniele La Barbera, et al.
Human Molecular Genetics|January 15, 2010
A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophreniaAndrés Ingason, Ina Giegling, Sven Cichon, et al.
Molecular Psychiatry|August 29, 2023
Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analysesNerisa Banaj, Daniela Vecchio, Fabrizio Piras, et al.
Human Molecular Genetics|October 24, 2008
Disruption of the neurexin 1 gene is associated with schizophreniaDan Rujescu, Andres Ingason, Sven Cichon, et al.
Molecular Psychiatry|October 15, 2024
Methylomic signature of current cannabis use in two first-episode psychosis cohortsEmma L Dempster, Chloe C Y Wong, Joe Burrage, et al.
Psychological Medicine|October 17, 2019
An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortiumTing Yat Wong, Joaquim Radua, Edith Pomarol-Clotet, et al.
Nature|August 1, 2008
Large recurrent microdeletions associated with schizophreniaHreinn Stefansson, Dan Rujescu, Sven Cichon, et al.
Pageof 15